Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
SABI Mind
Multidisciplinary Association for Psychedelics Studies Public Benefit Corporation
Psygen
National Institute on Drug Abuse (K01DA049219)
- License Information
-
More Information
Article History
Accepted: 16 May 2023
First Online: 22 May 2023
Declarations
:
: The study was co-sponsored by SABI Mind, the Multidisciplinary Association of Psychedelic Studies Public Benefits Corp. (MAPS PBC), and Psygen.
: The survey was ethics reviewed by Advarra (protocol # Pro00059863).
: Online informed consent was obtained from all the study participants.
: Dr. Boehnke has received grant funding from Tryp Therapeutics and Algae Sciences. He sits on a Data Safety and Monitoring Committee (unpaid) for Vireo Health. Dr. Boehnke’s effort on this publication was partially supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number K01DA049219 (KFB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Philippe Lucas PhD is President of SABI Mind, one of the co-sponsors of this study.
